Physician profile
Baseer U Ahmad
NPI 1114160918
$1,995.94
in general payments reported to CMS, 2019-2025
11 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2021: $359 · 2022: $61.96 · 2023: $120 · 2024: $346 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $704.46 | 2021-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $422.54 | 2019 | |
| Dutch Ophthalmic, USA | $286.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $151.22 | 2019 | |
| Genentech USA, INC. | $115.36 | 2024 | Vabysmo |
| Astrazeneca Pharmaceuticals Lp | $93.85 | 2019 | |
| Pfizer INC. | $90.97 | 2019 | |
| Genentech, INC. | $82.29 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.15 | 2019 | |
| Notal Vision, INC. | $16.40 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $15.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baseer Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.